[Value of quantification of p24 antigen in plasma as a prognostic marker of survival in a cohort of 251 HIV-positive patients] NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Value of quantification of p24 antigen in plasma as a prognostic marker of survival in a cohort of 251 HIV-positive patients]

An Med Interna. 1998 Dec;15(12):647-9. Unique Identifier : AIDSLINE MED/99138546
Rubio Caballero M; Nogues Biau A; Falguera Sacrest M; Puig Gatnau T; Lorente L; Servicio de Medicina Interna, Hospital Universitario Arnau de; Vilanova, Lleida.

Abstract: OBJECTIVE: To analyse plasma p24 antigen as a marker of survival in a cohort of HIV-infected patients whose time of seroconversion is unknown. DESIGN: Prospective cohort study. SETTING: AIDS Unit in a teaching hospital. PATIENTS: 251 patients were studied, most on antiretroviral therapy. Mean initial CD4 cell counts were 376 x 106/ 1 (range: 0.8-1350). 51 cases had been diagnosed previously with AIDS. METHODS: Analysis of survival, according to initial plasma p24 antigen was performed by Kaplan-Meier test. Relative risks were calculated by Cox's proportional hazards model. RESULTS: During a follow-up period of 24 months, 46 patients died. Relative risk (RR) of death related to the group with p24 antigen = < 40 pg/ml was 3.32 when p24 antigen > 40 pg/ml (p = 0.0001). CD4+ cell levels adjusting, the result was 2.47 (CI 95% 1.37-4.46) (p = 0.0027). CONCLUSIONS: Plasma levels of p24 antigen is useful as a marker of the risk of death and it behaves as a independent prognostic marker in our patients. P24 antigen = < 40 pg/ml is associated with a better prognosis.
Keywords: JOURNAL ARTICLE marcador pronostico de supervivencia en una cohorte de 251 pacientes VIH +. Biological Markers Cohort Studies Comparative Study CD4 Lymphocyte Count Data Interpretation, Statistical English Abstract Follow-Up Studies Human HIV Core Protein p24/*BLOOD HIV Seropositivity/IMMUNOLOGY/*MORTALITY Prognosis Prospective Studies Risk Support, Non-U.S. Gov't Survival Analysis Time FactorsKWDjournalarticlemarcadorpronosticodesupervivenciaenunacohortede251pacientesvih+KWDbiologicalmarkerscohortstudiescomparativestudycd4lymphocytecountdatainterpretation,statisticalenglishabstractfollow-upstudieshumanhivcoreproteinp24/KWDbloodhivseropositivity/immunology/KWDmortalityprognosisprospectivestudiesrisksupport,non-uKWDsKWDgov'tsurvivalanalysistimefactors
990530
A9950965

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .